NCT01903330View on ClinicalTrials.gov

ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

March 31, 2026

Study Completion Date

June 30, 2026

Conditions
GlioblastomaGliosarcoma
Interventions
DRUG

ERC1671

Given intradermally

DRUG

GM-CSF

Given intradermally

DRUG

Cyclophosphamide

Given PO. Drug class: Alkylating Agent; Antineoplastic Agent; Nitrogen Mustard.

DRUG

Oral Control (Sucrose pill)

Given PO

DRUG

Injectable control (Sodium Chloride Injection United States Pharmacopeia (USP) (0.9%))

Given IV

DRUG

Bevacizumab/Bevacizumab Biosimilar

Given IV. Drug class: Immunological Agent; Monoclonal Antibody.

Trial Locations (3)

92868

University of California, Irvine, Orange

02114

Massachusetts General Hospital Cancer Center, Boston

02215

Dana Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
collaborator

University of California, Irvine

OTHER

lead

Epitopoietic Research Corporation

INDUSTRY

NCT01903330 - ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme | Biotech Hunter | Biotech Hunter